HDAC9 and cancer: Moreover, animacroxam also proved its suitability for the treatment of cisplatin‐refractory/insensitive cancer cells as its modes of action do not require the formation of DNA intrastrand crosslink adducts, but rather attacks cancer cells at the level of cytoskeletal integrity and HDAC activity.